CTTI \u2014 Clinical Trials Transformation Initiative<\/strong> is especially close to what you’re describing. It is a public-private partnership co-founded by Duke University and the FDA<\/strong> specifically to develop and promote practices that improve clinical-trial quality, efficiency and patient-centeredness. Its work includes Quality by Design, decentralized trials, safety reporting and simplifying data collection.<\/p>\n ICH \u2014 International Council for Harmonisation<\/strong> is even more important if your goal is something that can eventually be used worldwide. ICH creates harmonized drug-development standards across regulatory jurisdictions. Its E6(R3) framework is moving clinical research toward proportionality, risk-based quality management and more flexible trial technologies.<\/p>\n FDA<\/strong> itself has major programs involving decentralized trials, digital technologies, complex innovative designs, master protocols and New Approach Methodologies. This is not merely theoretical research; these concepts are increasingly entering regulatory guidance.<\/p>\n EMA \/ ACT EU<\/strong> is pursuing a similar transformation in Europe. ACT EU explicitly aims to change how trials are initiated, designed and conducted while promoting high-quality, safe and effective medicines. Europe is also working on decentralized trials and complex methodologies such as master protocols and Bayesian approaches.<\/p>\n TransCelerate BioPharma<\/strong> brings pharmaceutical companies, regulators, CROs, research sites and technology providers together to eliminate redundant processes. Projects include risk-based monitoring, decentralized methods, eConsent, digital data flow and reducing repeated site qualification and training.<\/p>\n Critical Path Institute (C-Path)<\/strong> develops regulatory-science tools such as biomarkers, quantitative models and clinical-trial simulators. In May 2026 it also launched a coalition specifically aimed at accelerating validation and regulatory adoption of human-relevant New Approach Methodologies.<\/p>\n NIH\/NCATS<\/strong> is particularly interesting for your idea of making trials safer before humans are exposed<\/em>. Its Tissue Chip program develops human-cell-based organ systems for predicting drug safety and toxicity, and its \u201cClinical Trials on a Chip\u201d work is exploring how these technologies can improve trial development and design.<\/p>\n There is still something missing: one universally usable, open clinical-trial operating system<\/strong> connecting laboratories, hospitals, ethics committees, regulators and participants internationally.<\/p>\n Conceptually, such a system could combine a standardized protocol generator, automated regulatory documentation, shared control-group data where scientifically justified, real-time safety surveillance, electronic consent, wearable monitoring, standardized CDISC\/FHIR data, adaptive statistics, trial simulation, organ-on-chip screening and independent human-safety oversight.<\/p>\n The important principle would be:<\/p>\n Automate administration\u2014not ethics. Reduce unnecessary testing\u2014not necessary safety testing. Use AI to detect risk\u2014not to make unsupervised decisions about human safety.<\/strong><\/p>\n That could be a genuinely worthwhile research program in its own right. The pieces already exist; the larger challenge is integrating and validating them into a system that regulators around the world can trust<\/strong>.<\/p>\n If this idea is connected to the project on your website, CTTI, C-Path, NCATS and ICH are probably the four organizations I would study first<\/strong>. They are unusually close to the exact problem you’re proposing.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n Organizations seriously working on exactly this problem CTTI \u2014 Clinical Trials Transformation Initiative is especially close to what you’re describing. It is a public-private partnership co-founded by Duke University and the FDA specifically to develop and promote practices that improve clinical-trial quality, efficiency and patient-centeredness. Its work includes Quality by Design, decentralized trials, safety reporting […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[46,35,28],"tags":[],"_links":{"self":[{"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/posts\/2778"}],"collection":[{"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/comments?post=2778"}],"version-history":[{"count":1,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/posts\/2778\/revisions"}],"predecessor-version":[{"id":2779,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/posts\/2778\/revisions\/2779"}],"wp:attachment":[{"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/media?parent=2778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/categories?post=2778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jonathandespres.com\/cryonicsrevival\/wp-json\/wp\/v2\/tags?post=2778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}The larger opportunity<\/h3>\n